As Ptc Therapeutics INC (PTCT) Valuation Rose, Shareholder Spark Investment Management LLC Has Trimmed Its Stake

July 27, 2018 - By Billy Entrekin

PTC Therapeutics, Inc. (NASDAQ:PTCT) LogoInvestors sentiment increased to 1.26 in Q1 2018. Its up 0.28, from 0.98 in 2017Q4. It improved, as 16 investors sold PTCT shares while 37 reduced holdings. 36 funds opened positions while 31 raised stakes. 38.49 million shares or 8.57% more from 35.45 million shares in 2017Q4 were reported. Moreover, Renaissance Technologies Lc has 0.01% invested in PTC Therapeutics, Inc. (NASDAQ:PTCT) for 219,200 shares. Geode Mngmt Llc holds 365,322 shares. Guggenheim reported 65,289 shares. Swiss Comml Bank, a Switzerland-based fund reported 73,565 shares. Peak6 Investments Lp invested in 55,443 shares. Great Point Partners Ltd Liability stated it has 0.01% in PTC Therapeutics, Inc. (NASDAQ:PTCT). Tekla Cap Mgmt Ltd Liability Corp reported 24,299 shares. Parametric Portfolio Assoc Limited Liability Company stated it has 0% in PTC Therapeutics, Inc. (NASDAQ:PTCT). California Pub Employees Retirement System reported 39,309 shares stake. 43,224 are owned by Group One Trading Lp. Raymond James Fincl accumulated 10,083 shares. Royal Bancorporation Of Canada stated it has 0% in PTC Therapeutics, Inc. (NASDAQ:PTCT). 655,500 were accumulated by Spark Invest Management Limited Company. 145,000 were reported by Opaleye Inc. Sei Investments owns 0% invested in PTC Therapeutics, Inc. (NASDAQ:PTCT) for 1,000 shares.

Since June 1, 2018, it had 0 insider buys, and 2 sales for $1.15 million activity. Souza Marcio also sold $178,829 worth of PTC Therapeutics, Inc. (NASDAQ:PTCT) shares.

Spark Investment Management Llc decreased its stake in Ptc Therapeutics Inc (PTCT) by 36.8% based on its latest 2018Q1 regulatory filing with the SEC. Spark Investment Management Llc sold 381,700 shares as the company’s stock rose 17.15% while stock markets declined. The hedge fund held 655,500 shares of the health care company at the end of 2018Q1, valued at $17.74 million, down from 1.04 million at the end of the previous reported quarter. Spark Investment Management Llc who had been investing in Ptc Therapeutics Inc for a number of months, seems to be less bullish one the $1.83B market cap company. The stock increased 4.23% or $1.59 during the last trading session, reaching $39.17. About 506,790 shares traded. PTC Therapeutics, Inc. (NASDAQ:PTCT) has risen 144.83% since July 27, 2017 and is uptrending. It has outperformed by 132.26% the S&P500.

Spark Investment Management Llc, which manages about $1.26 billion and $1.57B US Long portfolio, upped its stake in Shutterstock Inc (NYSE:SSTK) by 95,300 shares to 205,500 shares, valued at $9.89M in 2018Q1, according to the filing. It also increased its holding in Pbf Energy Inc (NYSE:PBF) by 112,802 shares in the quarter, for a total of 791,402 shares, and has risen its stake in Fortinet Inc (NASDAQ:FTNT).

Analysts await PTC Therapeutics, Inc. (NASDAQ:PTCT) to report earnings on August, 14. They expect $-0.21 EPS, up 52.27 % or $0.23 from last year’s $-0.44 per share. After $-0.46 actual EPS reported by PTC Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -54.35 % EPS growth.

More important recent PTC Therapeutics, Inc. (NASDAQ:PTCT) news were published by: which released: “PTC Therapeutics to acquire Agilis Biotherapeutics for $200M; shares up 8.5%” on July 19, 2018, also published article titled: “After-Hours Stock Movers 07/19 (PTCT) (CE) (ISRG) Higher; (SKX) (ZYNE) (FTD) Lower (more…)”, published: “Mid-Morning Market Update: Markets Mostly Flat; Honeywell Tops Q2 Expectations” on July 20, 2018. More interesting news about PTC Therapeutics, Inc. (NASDAQ:PTCT) was released by: and their article: “PTC Therapeutics Wins Big With Agilis Biotherapeutics Acquisition” with publication date: July 20, 2018.

PTC Therapeutics, Inc. (NASDAQ:PTCT) Ratings Coverage

Among 6 analysts covering PTC Therapeutics (NASDAQ:PTCT), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. PTC Therapeutics has $50 highest and $24 lowest target. $33.50’s average target is -14.48% below currents $39.17 stock price. PTC Therapeutics had 11 analyst reports since January 29, 2018 according to SRatingsIntel. As per Wednesday, March 7, the company rating was maintained by Barclays Capital. Cowen & Co maintained the stock with “Hold” rating in Wednesday, April 18 report. Barclays Capital downgraded the stock to “Underweight” rating in Wednesday, April 4 report. The rating was upgraded by RBC Capital Markets to “Outperform” on Monday, June 18. The stock of PTC Therapeutics, Inc. (NASDAQ:PTCT) earned “Hold” rating by RBC Capital Markets on Monday, January 29. The firm has “Equal-Weight” rating given on Wednesday, June 20 by Barclays Capital. RBC Capital Markets maintained PTC Therapeutics, Inc. (NASDAQ:PTCT) on Wednesday, March 7 with “Hold” rating. The stock of PTC Therapeutics, Inc. (NASDAQ:PTCT) has “Buy” rating given on Tuesday, July 24 by Citigroup. On Monday, June 18 the stock rating was upgraded by William Blair to “Outperform”. Citigroup maintained it with “Buy” rating and $35 target in Thursday, February 22 report.

PTC Therapeutics, Inc. (NASDAQ:PTCT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.